share_log

Mustang Bio Analyst Ratings

Mustang Bio Analyst Ratings

野馬生物分析師評級
Benzinga ·  2023/08/24 12:00
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/24/2023 516.44% Cantor Fitzgerald → $18 Reiterates Overweight → Overweight
08/16/2023 756.16% HC Wainwright & Co. → $25 Reiterates Buy → Buy
08/15/2023 447.95% BTIG $20 → $16 Maintains Buy
08/15/2023 756.16% HC Wainwright & Co. → $25 Reiterates Buy → Buy
06/16/2023 584.93% BTIG $4 → $20 Maintains Buy
06/16/2023 756.16% HC Wainwright & Co. → $25 Reiterates Buy → Buy
05/15/2023 139.73% HC Wainwright & Co. → $7 Reiterates Buy → Buy
03/30/2023 139.73% HC Wainwright & Co. → $7 Reiterates → Buy
11/16/2022 36.99% BTIG $8 → $4 Maintains Buy
01/24/2022 105.48% B. Riley Securities $13 → $6 Maintains Buy
05/18/2021 276.71% BTIG → $11 Initiates Coverage On → Buy
12/23/2020 345.21% B. Riley FBR → $13 Reinstates → Buy
10/02/2020 208.22% B. Riley Securities → $9 Initiates Coverage On → Buy
05/12/2020 345.21% Oppenheimer $15 → $13 Maintains Outperform
11/20/2019 139.73% Cantor Fitzgerald → $7 Assumes → Overweight
08/13/2019 HC Wainwright & Co. Initiates Coverage On → Buy
08/13/2019 139.73% HC Wainwright & Co. → $7 Initiates Coverage On → Buy
06/21/2019 139.73% Cantor Fitzgerald → $7 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年08月24日 516.44% 康託·菲茨傑拉德 →$18 重申 超重→超重
08/16/2023 756.16% HC Wainwright公司 →$25 重申 購買→購買
2023年08月15日 447.95% BTIG $20→$16 維護
2023年08月15日 756.16% HC Wainwright公司 →$25 重申 購買→購買
06/16/2023 584.93% BTIG $4→$20 維護
06/16/2023 756.16% HC Wainwright公司 →$25 重申 購買→購買
2023年05月15日 139.73% HC Wainwright公司 →$7 重申 購買→購買
03/30/2023 139.73% HC Wainwright公司 →$7 重申 →購買
2022年11月16日 36.99% BTIG $8→$4 維護
01/24/2022 105.48% B.萊利證券 $13→$6 維護
2021/05/18 276.71% BTIG →$11 開始承保 →購買
12/23/2020 345.21% B.萊利FBR →$13 恢復 →購買
10/02/2020 208.22% B.萊利證券 →$9 開始承保 →購買
2020/05/12 345.21% 奧本海默 $15→$13 維護 跑贏大盤
2019年11月20日 139.73% 康託·菲茨傑拉德 →$7 假設 →超重
2019年08月13日 - HC Wainwright公司 開始承保 →購買
2019年08月13日 139.73% HC Wainwright公司 →$7 開始承保 →購買
2019年06月21日 139.73% 康託·菲茨傑拉德 →$7 開始承保 →超重

What is the target price for Mustang Bio (MBIO)?

野馬生物(MBio)的目標價是多少?

The latest price target for Mustang Bio (NASDAQ: MBIO) was reported by Cantor Fitzgerald on August 24, 2023. The analyst firm set a price target for $18.00 expecting MBIO to rise to within 12 months (a possible 516.44% upside). 9 analyst firms have reported ratings in the last year.

野馬生物(納斯達克:mBio)的最新目標價是由坎託·菲茨傑拉德於2023年8月24日報道的。這家分析公司將目標價定為18美元,預計mBio將在12個月內上漲(可能上漲516.44)。去年有9家分析公司公佈了評級。

What is the most recent analyst rating for Mustang Bio (MBIO)?

野馬生物(Mustang Bio)最新的分析師評級是多少?

The latest analyst rating for Mustang Bio (NASDAQ: MBIO) was provided by Cantor Fitzgerald, and Mustang Bio reiterated their overweight rating.

野馬生物(納斯達克代碼:MBIO)的最新分析師評級由坎託·菲茨傑拉德提供,野馬生物重申其增持評級。

When is the next analyst rating going to be posted or updated for Mustang Bio (MBIO)?

野馬生物(Mustang Bio)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mustang Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mustang Bio was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與野馬生物的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。野馬生物的上一次評級是在2023年8月24日提交的,所以你應該預計下一次評級將在2024年8月24日左右的某個時候公佈。

Is the Analyst Rating Mustang Bio (MBIO) correct?

分析師對野馬生物(Mustang Bio)的評級正確嗎?

While ratings are subjective and will change, the latest Mustang Bio (MBIO) rating was a reiterated with a price target of $0.00 to $18.00. The current price Mustang Bio (MBIO) is trading at is $2.92, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的野馬生物(Mustang Bio)評級被重申,目標價在0.00美元至18.00美元之間。野馬生物(Mustang Bio)目前的交易價格為2.92美元,在分析師的預測區間內。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論